Case report: Sequential inotuzumab, blinatumomab, and chemotherapy with concurrent donor lymphocyte infusions induce complete remission in relapsed pre‐B acute lymphoblastic leukemia

Abstract

AbstractThis case report presents the successful management of relapsed/refractory (r/r) B‐cell acute lymphoblastic leukemia in a 54‐year‐old male post‐allogeneic hematopoietic cell transplantation. The combinatorial approach of sequential antibody treatment (Inotuzumab [InO] and Blinatumomab [Blina]) combined with three donor lymphocyte infusions (DLI) applications and cytoreductive chemotherapy‐induced sustained complete molecular remission as documented at the last follow‐up 30 months later. This case highlights the feasibility and potential synergistic efficacy of a Blina/DLI regimen and supports the hypothesis that T‐cell engagers could enhance the DLI effect. Furthermore, the co‐administration of InO, Blina, DLI, and cytoreductive chemotherapy was proven to be feasible without severe adverse events.